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ABSTRACT
Background: To investigate the serum level of hepcidin and its relationship with cardiovascular disease
(CVD) in maintenance hemodialysis (MHD) patients. Methods: Blood was obtained from 75 MHD
patients before undergoing hemodialysis and 20 healthy controls. Serum hepcidin, advanced oxidation
protein products (AOPP) and interleukin (IL)-6 were measured by enzyme-linked immunosorbant assay
(ELISA). Spearman correlation, and binary logistic regression linear regression analyses were used to
assess the relationship between serum hepcidin and other parameters. Results: The serum level of
hepcidin, AOPP and IL-6 was significantly up-regulated in MHD patients compared with the control (P
< 0.05). Furthermore, serum hepcidin levels in patients with CVD were higher than those in patients
without CVD (P < 0.05). In all MHD patients, serum hepcidin level was correlated positively with
erythropoietin (EPO) dose per week (r 5 0.251, P 5 0.030), EPO resistance index (r 5 0.268, P 5
0.020), ferritin (r 5 0.814, P < 0.001), transferin saturation (TSAT, r 5 0.263, P 5 0.023), AOPP (r 5
0.280, P 5 0.049), high sensitive C reactive protein (r 5 0.151, P 5 0.006), IL-6 (r 5 0.340, P 5 0.003)
and left ventricular mass index (LVMI, r 5 0.290, P 5 0.033). Moreover, it was negatively correlated
with serum pre-albumin (r 5 0.266, P 5 0.021), total iron-binding capacity (TIBC, r 5 0.458, P <
0.001), unsaturated iron-binding capacity (UIBC, r 5 0.473, P < 0.001) and transferrin (r 5 0.487, P
< 0.001). Linear regression analysis showed that ferritin (b 5 0.708, P < 0.001), TIBC (b 5 0.246, P 5
0.032) and IL-6 (b 5 0.209, P 5 0.041) were independently associated with hepcidin. Results of binary
logistic regression analysis suggested that higher serum hepcidin level (>249.2 ng/mL) was positively and
independently related to CVD (OR 5 1.32, 95% CI [1.20–9.56], P 5 0.043). Conclusions: Serum hepcidin
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level is associated with CVD in MHD patients, indicating that hepcidin may be a novel biomarker and
therapeutic target for CVD.
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INTRODUCTION
Cardiovascular disease (CVD) is responsible for approximately 45% deaths in patients under
hemodialysis, but its pathogenesis is very complex [1]. The event incidence of CVD is high in
the first few weeks after initiation of hemodialysis and is associated with systemic inflammation
and endothelial dysfunction in hemodialysis patients [2, 3]. CVD was proved to be associated
with worse cognitive performance in maintain hemodialysis (MHD) patients [4]. Numerous
factors including hypertension, fluid overload, systemic inflammation, lipid disorders, wound
healing and coagulation, etc. contribute to CVD in this population [5]. However, it remains
unclear which factor in MHD patients is related to CVD. Therefore, discovering new factors for
understanding the pathophysiology of CVD and eventually finding new treatments for CVD are
needed.
Hepcidin is an iron-regulatory peptide hormone, a 25-amino acid type-II acute-phase
protein analogous to ferritin, which plays an important role in iron homeostasis [6, 7]. The
expression of the key iron regulatory hormone hepcidin is regulated by iron availability,
inflammation, hormones, hypoxia, and anaemia. Hepcidin shows antimicrobial activity in hu-
man hepatic cells in case of iron overload or inflammation. The inflammatory cytokines, such as
IL-1b and IL-6 can induce hepcidin secretion [8, 9]. Hepcidin is associated with iron absorption
in the intestine and performs its different functions via a single biochemical mechanism: hep-
cidin-ferroportin interaction [10, 11]. Furthermore, hepcidin stimulates degradation of ferro-
portin, and thus reduces iron supply to the bone marrow and decrease serum iron levels [12].
Recently, some scholars have suggested that high serum levels of hepcidin in hemodialysis
patients can cause iron retention in vascular endothelial cells and plaque macrophages, and
cause CVD through oxidative stress [13]. In an elderly general population, it is found that
fibrinogen and g-glutamyltransferase are directly related to hepcidin, but hepcidin is not
correlated to CVD [14]. So far the relationship between serum hepcidin and CVD in MHD
patients has not been studied in China. The purpose of this study is to explore the relationship
between serum hepcidin level and CVD in MHD patients, and to provide new ideas for the
treatment of CVD in MHD patients.
MATERIALS AND METHODS
Patients
In January 2019, a total of 75 MHD patients were recruited in the Blood Purification Center,
Shanghai Yangsi Hospital and Yantai Affiliated Hospital of Binzhou Medical College, China. For
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hemodialysis, dialyzers were disposable, and the material of membrane was polysulfone with an
area of 1.2–1.6 m2. The dialysis water was treated with reverse osmosis, standard bicarbonate
dialysate, and the dialysate flow was 500 mL/min. The blood flow was 200–300 mL/min. He-
modialysis was taken 3 times a week, 4 h each session. Anticoagulation was performed with
normal heparin or low molecular weight heparin. The vascular access was autogenous arte-
riovenous fistula or central venous catheterization. After 1 year of follow-up, CVD was defined
as myocardial infarction, angina pectoris, heart failure, cerebral hemorrhage, cerebral infarction,
internal fistula occlusion or vascular reconstruction including cardiac and peripheral blood
vessels. Clinical data for patients including age, gender, body mass index (BMI), erythropoietin
(EPO), EPO resistance index, smoking history, diabetes history, CVD history and dialysis
related data were collected. 20 healthy people without obesity and smoking history were selected
as the control.
Inclusion criteria: Patients who had MHD for more than 3 months; patients who were over
18 years old and in a stable condition. Exclusion criteria: Patients with severe heart failure, liver
disease, severe infection, active tuberculosis, malignant tumor, active inflammatory disease
taking immunosuppressant; patients with acute cardiovascular events in the past month; pa-
tients with peritoneal dialysis or kidney transplantation converted to hemodialysis; patients with
recent surgery or blood transfusion history; and those who did not want to participate in this
study. The study was approved by the Ethical Committee of Shanghai Yangsi Hospital
(Ysyyllwj-208-11).
Laboratory examination
Hemoglobin (Hb), leukocyte count (WBC), serum creatinine (SCR), urea nitrogen (BUN), uric
acid, calcium (CA), phosphorus (P), whole parathyroid hormone (iPTH), albumin, prealbumin,
triglyceride (TG), total cholesterol (TCH), high density lipoprotein cholesterol (HDL-C), low
density lipoprotein cholesterol (LDL-C), total iron-binding capacity (TIBC), unsaturated iron-
binding capacity (UIBC), serum iron, transferrin, ferritin and high sensitivity C reactive protein
(hsCRP) were measured by widely used methods. Cardiac troponin T (cTnT) and amino-ter-
minal pro-B-natriuretic peptide (NT-proBNP) were detected by electrochemiluminescence.
Transferrin saturation (TSAT) 5 serum iron/TIBC.
Serum ferritin, advanced oxidation protein products (AOPP) and IL-6 were determined
by enzyme-linked immunosorbent assay (ELISA). Briefly, blood was drawn from the pe-
ripheral vein of patients with MHD before dialysis or the healthy control on an empty
stomach, in the morning. The blood was placed in a serum tube, and centrifuged at 1,000 g
for 10 min. The serum was collected and stored at 70 8C for further testing. The samples
were thawed at room temperature and tested by ELISA Kits (Wuhan Cusabio Company,
China) according to the instructions. The measured optical density value was used to make
the standard curve by Curve Expert Software, and the corresponding concentration of the
sample was calculated.
Measurement of carotid intima-media thickness
After hemodialysis, carotid intima-media thickness (IMT) was measured by Philips SD800 ul-
trasound with a probe frequency of 7.5 MHz. Briefly, patients took a supine position, and the
posterior wall of the proximal branch of the common carotid artery and 1 cm above the origin of
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the internal carotid artery of patients were measured. The real-time two-dimensional images of
the transverse and longitudinal axes of the common carotid artery and its branches were
continuously observed from the root of the neck. The end diastolic images were taken to
measure the vertical distance from the inner surface of the lumen to the outer surface of the
mesomembrane as the carotid IMT.
Echocardiography
All MHD patients underwent echocardiography within 2 h after HD by two experienced ul-
trasound doctors using a PHILIPS IE33 Doppler color ultrasound system with a probe frequency
of 3.5 MHz. Patients lay on their left side, with a standard long axis view of the left ventricle
beside the sternum. The systolic and diastolic wall thickness, the change of left ventricular
diameter and left ventricular ejection fraction (LVEF) were measured by the method recom-
mended by the American Society of Echocardiography. The left ventricular mass (LVM) was
calculated by Devereux formula [12]. LVM (g) 5 0.8 3 1.04 [(left ventricular end diastolic
diameter þ left ventricular posterior wall thickness þ interventricular septum thickness)3  left
ventricular end diastolic diameter3] þ 0.6. LVMI 5 LVM/height2.7.
Statistical analysis
Statistical Product and Service Solutions (SPSS) 19.0 software (SPSS Inc., Chicago, IL, USA) was
used for statistical analysis of the data. The continuity variables were first tested for normality.
The continuous variables of normal distribution were represented by x ± s, the continuous
variables of skew distribution were represented by median (interquartile spacing), and the
population data were represented by composition ratio. The differences between the two groups
were compared by nonparametric test, t-test and c2 test. Spearman correlation and linear
regression analysis (natural logarithm transformation of skew distribution data) were used to
analyze the correlation between hepcidin and each index. The correlation between CVD and
each index was analyzed by binary logistic regression. All tests were unpaired, and P < 0.05 was
considered statistically significant. All CIs were 95%.
RESULTS
General information of patients with MHD
General information of patients with MHD is shown in Table 1. A total of 75 patients un-
dergoing hemodialysis including 40 males and 35 females were evaluated in this study. The
mean age of patients was 59 years (range 49–72 years). The mean duration on dialysis was 44
months (range 25–92 months). The body mass index (BMI) was 21.9 ± 2.8 kg/m2. The mean
systolic blood pressure was 135.5 ± 22.4 mmHg and the mean diastolic blood pressure was 78.8
± 12.0 mmHg.
During the follow-up, 26 patients were found to have developed CVD (34.7%), including 8
cases of cerebral infarction (30.8%), 5 cases of myocardial infarction (19.2%), 4 cases of cerebral
hemorrhage (15.4%), 4 cases of heart failure (15.4%), 2 cases of angina pectoris (7.7%), 2 cases of
peripheral vascular disease (7.7%), and 1 case of internal fistula occlusion (3.8%).
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Table 1. Univariate analysis of correlation between serum hepcidin and clinical and laboratory indexes in
hemodialysis patients
x ± s or M* r P value
Age (Year) 59 (49–72) 0.109 0.355
BMI (kg/m2) 21.9 ± 2.8 0.112 0.341
Dialysis duration (month) 44 (25–92) 0.026 0.827
spKt/V 1.29 (1.18–1.59) 0.063 0.664
EPO dose (U/week) 6,000 (5,000–10,000) 0.251 0.030
EPO resistance index 1.17 (0.65–1.72) 0.268 0.020
Systolic blood pressure (mmHg) 135.5 ± 22.4 0.238 0.052
Diastolic blood pressure (mmHg) 78.8 ± 12.0 0.167 0.177
Serum albumin (g/L) 40.7 ± 2.8 0.052 0.660
Serum pre-albumin (g/L) 0.36 ± 0.09 0.266 0.021
Scr before dialysis (mmol/L) 1,006.1 ± 231.3 0.341 0.103
BUN before dialysis (mmol/L) 27.7 ± 6.5 0.124 0.294
Serum uric acid (mmol/L) 449.1 ± 92.4 0.097 0.461
Ca (mmol/L) 2.27 (2.19–2.47) 0.049 0.680
P (mmol/L) 2.07 (1.63–2.61) 0.323 0.105
Ca 3 P (mmol2/L2) 5.467 (3.52–6.76) 0.224 0.053
iPTH (pg/ml) 389.4 (195.6–591.7) 0.025 0.834
25(OH)D3 (nmol/ml) 27.1 (17.4–37.9) 0.030 0.801
Tch (mmol/L) 4.65 (4.20–5.47) 0.066 0.584
TG (mmol/L) 1.66 (1.39–2.15) 0.147 0.120
HDL-C (mmol/L) 1.19 ± 0.30 0.094 0.435
LDL-C (mmol/L) 2.74 ± 0.91 0.075 0.534
b2- microglobulin (mg/L) 31.0 (23.2–34.8) 0.205 0.082
Hb (g/L) 113.7 ± 11.1 0.028 0.809
WBC (109/L) 5.94 (5.39–7.06) 0.036 0.756
UIBC (mmol/L) 28.0 (23.0–33.0) 0.473 <0.001
TIBC (mmol/L) 40.0 (36.0–44.3) 0.458 <0.001
Transferrin (g/L) 1.97 (1.70–2.17) 0.487 <0.001
Ferritin (ng/ml) 164.7 (98.2–341.7) 0.814 <0.001
Serum iron (mmol/L) 11.2 (9.1–16.6) 0.060 0.612
TSAT (%) 29.1 (23.2–39.8) 0.263 0.023
Homocysteine (mmol/L) 30.9 (26.8–38.3) 0.053 0.668
AOPP (ng/mL) 336.6 (249.6–389.6) 0.280 0.049
NT-proBNP (pg/mL) 3,555 (1,409–12,125) 0.065 0.581
hsCRP (mg/L) 3.2 (1.4–7.1) 0.151 0.006
IL-6 (pg/mL) 45.9 (32.8–85.4) 0.340 0.003
cTnT (ng/mL) 0.043 (0.027–0.065) 0.014 0.907
IMT (cm) 0.8 (0.7–0.8) 0.132 0.347
LVMI (g/m2.7) 52.9 (42.1–63.9) 0.290 0.033
LVEF (%) 68 (62.5–70) 0.207 0.104
Note: Mean (M), body mass index (BMI), erythropoietin (EPO), urea nitrogen (BUN), leukocyte count
(WBC), hemoglobin (Hb), calcium (CA), phosphorus (P), serum creatinine (Scr), total cholesterol (Tch),
triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-
C), whole parathyroid hormone (iPTH), total iron binding capacity (TIBC), unsaturated iron bonding
capacity (UIBC), transferrin saturation (TSAT), advanced oxidation protein products (AOPP), cardiac
troponin T (cTnT), amino-terminal pro-B-natriuretic peptide (NT-proBNP), high sensitivity C reactive
protein (hsCRP), intima-media thickness (IMT), left ventricular mass index (LVMI), and left ventricular
ejection fraction (LVEF).
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Serum levels of hepcidin, AOPP and IL-6 in hemodialysis patients
There were 11 males and 9 females with mean age of 60 years (range 48–71 years) in the healthy
control group. There was no significant difference in gender and age between the MHD patients
and the control group (P > 0.05) (Table 1). Results of serum levels of hepcidin, AOPP and IL-6
in hemodialysis patients and the control are shown in Table 2. It was suggested that the levels of
serum hepcidin, AOPP and IL-6 in MHD patients were significantly higher than those in the
control group (P < 0.05).
In addition, serum ferritin levels were compared between MHD patients with CVD and
MHD without CVD patients. It was suggested that the level of serum ferritin in MHD patients
with CVD was significantly higher than that in non-CVD patients [335.9 (206.3–514.2) ng/mL
vs. 210.5 (133.6–392.3) ng/mL, P < 0.05] (data not shown).
Analysis of related factors of serum hepcidin in MHD patients
Spearman correlation analysis showed that the serum hepcidin level was positively correlated
with weekly EPO dose, EPO resistance index, ferritin, TSAT, AOPP, serum hsCRP, IL-6 and
LVMI. On the other hand, it was negatively correlated with serum prealbumin, TIBC, UIBC and
transferrin (Table 1). In addition, linear regression analysis showed that ferritin, TIBC and IL-6
were independently correlated with serum hepcidin level (Table 3).
Logistic regression analysis of risk factors for CVD
Risk factors for CVD were measured by logistic regression analysis. It was shown that higher
serum hepcidin (>249.2 ng/mL) was positively related to CVD (OR 5 1.32, 95% CI [1.20–9.56],
P 5 0.043). Age (OR 5 1.03, 95% CI [1.01–1.29], P 5 0.049) and smoking (OR 5 2.14, 95% CI
[1.17–14.05], P 5 0.043) were also associated with CVD (Table 4). The above results indicated
that smoking, old age and higher serum hepcidin were independent risk factors for CVD.
Table 2. Comparison of hepcidin, AOPP and IL-6 between hemodialysis patients and the control
Hepcidin (ng/mL) AOPP (ng/mL) IL-6 (pg/mL)
Control 84.7 (49.6–179.3) 78.8 (51.3–139.4) 33.5 (22.4–47.6)






Note: maintenance hemodialysis (MHD), advanced oxidation protein products (AOPP). p P < 0.05 vs.
control.





regression coefficient P value
Ferritin 0.789 0.708 <0.001
TIBC 5.795 0.246 0.032
IL-6 4.354 0.209 0.041
Note: TIBC: Total iron binding capacity.
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DISCUSSION
Hepcidin is a polypeptide discovered in 2000, which has anti-bacterial and anti-fungal functions. It
has been confirmed that hepcidin plays a key role in the regulation of iron metabolism balance in
the body [15, 16]. At present, it is believed that the targets of hepcidin in iron metabolism are
duodenal epithelial cells and monocyte macrophages. In the pathogenesis of anemia in chronic
diseases, the most important point is that the increase of hepcidin level leads to the abnormal
release of iron. The combination of hepcidin and its receptor membrane iron transporter blocks the
release of iron from macrophages and jejunal cells, and eventually results in functional or relative
iron deficiency [17–19]. The expression level of hepcidin is affected by the iron level in the body,
inflammation, erythropoiesis activity, hypoxia and other factors [20]. In recent years, the rela-
tionship between hepcidin, CVD and atherosclerosis has been reported in different populations.
These studies suggest that hepcidin may play an important role in atherosclerosis by capturing iron
from atherosclerotic plaque macrophages and increasing oxidative stress. Furthermore, hepcidin
can induce endothelial dysfunction by iron retention [17, 19, 21]. It has been shown that hepcidin is
independently related to arterial stiffness in hemodialysis patients by measuring brachial ankle
pulse wave velocity [22]. Weerd et al. followed up 405 patients with MHD for 3 years and found
that, after correction for inflammatory factors, hepcidin is associated with fatal and non-fatal
cardiovascular events [19]. Another study on menopausal women showed that the distribution of
iron in the body is determined by hepcidin and the ratio of hepcidin to ferritin, rather than the total
iron load of the body [23]. The above findings suggest that serum hepcidin may be a new marker
and a therapeutic target for CVD. Our results demonstrate that the serum hepcidin level in MHD
patients with CVD is significantly higher than that in non-CVD patients. Serum hepcidin is an
independent risk factor for CVD, which is consistent with the above reported results.
Left ventricular hypertrophy (LVH) is a significant predictor of cardiovascular morbidity and
mortality in patients undergoing long-term hemodialysis (HD) therapy [12]. This study in-
dicates that there is a positive correlation between hepcidin and LVMI. Considering the possible
correlation between hepcidin and arterial stiffness, the increase of arterial stiffness can cause the
left ventricular hypertrophy. In addition, it is also suggested that inflammation and other factors
can lead to the increase of hepcidin and left ventricular hypertrophy. AOPP is the product of
serum albumin oxidized by hypochlorite, and it is a protein crosslinked polymer containing
double tyrosine. AOPP mainly reflects the degree of protein oxidation, and it is also a stable
index reflecting the level of oxidative stress in the body [24]. This study also showed a positive
correlation between hepcidin and AOPP, which is consistent with data reported in the literature
about peritoneal dialysis patients [25].
In the present study, the levels of serum hepcidin, AOPP and IL-6 in MHD patients are
significantly higher than those in the normal control group, and the level of serum hsCRP is
Table 4. Logistic regression analysis of risk factors for CVD
OR 95% CI P value
Age (Every year of growth) 1.03 1.01–1.29 0.049
Smoking (Y/N) 2.14 1.17–14.05 0.031
Hepcidin (>249.2 ng/mL) 1.32 1.20–9.56 0.043
Note: cardiovascular disease (CVD), confidence interval (CI), odd ratio (OR).
Physiology International 107 (2020) 4, 491–500 497
significantly increased, indicating that there is widespread inflammation and oxidative stress in
MHD patients. Results of this study are consistent with the previous research [26]. Additionally,
there is a positive correlation between serum hepcidin and hsCRP and IL-6 in MHD patients,
indicating that the increase of serum hepcidin in MHD patients is related to the state of inflam-
mation, as reported in a previous study [27]. Some studies have shown that IL-6 can regulate the
expression of the hepcidin gene by the following mechanism: IL-6 can activate the transcription
activator of ferritin by combining with signal transduction and transcription activator 3 (STAT3),
thereby increasing the synthesis of hepcidin [28, 29]. The linear regression analysis in our study
showed that there is an independent correlation between hepcidin and IL-6, which supports the
above conclusions. Moreover, there is a negative correlation between hepcidin and prealbumin,
which may be related to the malnutrition of MHD patients caused by the inflammatory state.
The results of this study show that serum hepcidin is positively correlated with hepcidin and
TSAT, whereas it is negatively correlated with transferrin, TIBC and UIBC. Linear regression
analysis demonstrated that hepcidin is independently correlated with ferritin and TIBC, which
verifies that hepcidin is closely related to the storage and utilization of iron, and it is a key
humoral regulator of iron metabolism. The results are consistent with our previous studies on
non-MHD patients [14, 30]. We also proved that there is a positive correlation between hepcidin
and weekly EPO dose and EPO resistance index, suggesting that the over-expression of hepcidin
may be one cause of EPO resistance in MHD patients, and the decrease of the ferritin level may
increase the sensitivity to EPO. This is consistent with findings in animal experiments and
clinical research, which provided evidence that the over-expression of hepcidin can weaken the
sensitivity of the body to EPO [31, 32].
There are still several limitations in this study. First, the sample size is relatively small, which
might affect the results. Second, there are no gold standards to identify the presence of CVD.
Third, there is a lack of imaging of CVD. Finally, it is unknown whether other factors may be
associated with the hemodialysis procedure in patients with and without CVD. Future studies
with larger sample size are needed for establishing the roles of hepcidin in CVD development in
patients under MHD, and also for evaluating their predictive values in CVD diagnosis.
CONCLUSION
In summary, iron load, inflammatory state, application of iron and EPO all affect the expression
of hepcidin in MHD patients. The increase of serum hepcidin level is related to CVD. Laboratory
animal models abroad have shown that inhibition of hepcidin expression can reduce the iron
content of macrophages and increase the cholesterol outflow capacity, resulting in the decrease of
foam cells and the reduction of atherosclerosis [33]. In the future, a cohort study with a larger
sample size is needed to further verify the relationship between hepcidin and CVD under MHD.
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